The combination of ibrutinib and venetoclax may have synergistic anti-tumor effects, since ibrutinib forces CLL cells from LNs to the PB where they become fully dependent on Bcl-2, and thus vulnerable to venetoclax [16]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.